NHLBI Progenitor Cell Translational Consortium (PCTC)

NHLBI Progenitor Cell Translational Consortium – Clinical Translation Studies, $50, 000 Award

Background

The goal of the NHLBI Progenitor Cell Translational Consortium (PCTC) is to translate advances in progenitor cell biology towards application to heart, lung, and blood diseases. The initiative will focus on the use of progenitor cell-based disease models to understand disease mechanisms and to develop novel therapies, and the application of progenitor cell-based therapies for the treatment of heart, lung, and blood diseases.

NHLBI Progenitor Cell Translational Consortium (PCTC)

Steering Committee Conference Call

Thursday, July 25, 2019, 4:00 - 5:00 PM, EDT

(3-4 PM, CDT, 2-3 PM, MDT, 1-2 PM, PDT)

Conference dial-in number: 1-800-882-3610, enter passcode 5748013 followed by #

Draft Agenda v1.0

PCTC Jump Start Award Program

Purpose:

To provide the PCTC with a mechanism to quickly award small grants to junior faculty (less than 5 years from their appointment to Assistant Professor), Research Associates, Graduate Students, Fellows and Postdocs to support a well-defined specific aim. The aim should involve at least one of the following, with priority given to proposals that incorporate two:

1.     The application of new technology to an existing translational research question

Drs. Wellington Cardoso, Benjamin J van Soldt, and colleagues report on nucleocytoplasmic shuttling of Yap and differentiation of the lung epithelium during morphogenesis.

[03Apr2019 Development]

Benjamin J. van Soldt, Jun Qian, Jiao Li, Nan Tang, Jining Lu, and Wellington V. Cardoso

Link to full article:

Yap and Its Subcellular Localization Have Distinct Compartment-Specific Roles in the Developing Lung